Total Payments
$79,796
2024 Payments
$4,586
Companies
9
Transactions
118
Medicare Patients
338
Medicare Billing
$76,874
Payment Breakdown by Category
Consulting$40,983 (51.4%)
Travel$33,854 (42.4%)
Food & Beverage$3,852 (4.8%)
Research$1,087 (1.4%)
Education$19.78 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $40,983 | 9 | 51.4% |
| Travel and Lodging | $33,854 | 43 | 42.4% |
| Food and Beverage | $3,852 | 63 | 4.8% |
| Unspecified | $1,087 | 1 | 1.4% |
| Education | $19.78 | 2 | 0.0% |
Payments by Type
General
$78,709
117 transactions
Research
$1,087
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $21,180 | 15 | $0 (2019) |
| Merck Sharp & Dohme LLC | $19,694 | 27 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $12,580 | 19 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $12,142 | 44 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $7,595 | 6 | $0 (2017) |
| AstraZeneca UK Limited | $5,221 | 4 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $1,087 | 1 | $0 (2020) |
| Stryker Corporation | $171.90 | 1 | $0 (2021) |
| EISAI INC. | $124.38 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,586 | 5 | AstraZeneca UK Limited ($2,474) |
| 2023 | $11,806 | 25 | Merck Sharp & Dohme LLC ($8,732) |
| 2022 | $1,525 | 7 | E.R. Squibb & Sons, L.L.C. ($1,525) |
| 2021 | $171.90 | 1 | Stryker Corporation ($171.90) |
| 2020 | $1,113 | 3 | Regeneron Pharmaceuticals, Inc. ($1,087) |
| 2019 | $21,402 | 22 | GENZYME CORPORATION ($14,287) |
| 2018 | $28,219 | 40 | Regeneron Healthcare Solutions, Inc. ($12,566) |
| 2017 | $10,973 | 15 | AstraZeneca Pharmaceuticals LP ($7,595) |
All Payment Transactions
118 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/22/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
| 09/14/2024 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $76.14 | General |
| 06/14/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $874.02 | General |
| 05/13/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $83.67 | General |
| 04/23/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $1,154.71 | General |
| 09/28/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $324.66 | General |
| 09/27/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $324.66 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $645.38 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $575.00 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $141.69 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $129.23 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $60.00 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $51.14 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $49.75 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $28.00 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $25.62 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $25.00 | General |
| 09/20/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $14.00 | General |
| 09/13/2023 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,710.00 | General |
| 09/13/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 09/08/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $548.33 | General |
| Category: ONCOLOGY | ||||||
| 09/08/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $116.67 | General |
| Category: ONCOLOGY | ||||||
| 09/08/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: ONCOLOGY | ||||||
| 09/08/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LIBTAYO CLINICAL PUBLICATION PROGRAM | Regeneron Pharmaceuticals, Inc. | $1,087 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 85 | 223 | $98,479 | $22,160 |
| 2022 | 3 | 63 | 184 | $81,228 | $18,741 |
| 2021 | 4 | 90 | 221 | $95,872 | $22,154 |
| 2020 | 4 | 100 | 225 | $60,188 | $13,819 |
Total Patients
338
Total Services
853
Medicare Billing
$76,874
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 35 | 148 | $70,744 | $16,151 | 22.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 38 | 63 | $20,475 | $4,389 | 21.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 12 | 12 | $7,260 | $1,621 | 22.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 23 | 119 | $57,120 | $13,431 | 23.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 29 | 54 | $17,442 | $3,775 | 21.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 11 | 11 | $6,666 | $1,536 | 23.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 32 | 142 | $68,586 | $15,986 | 23.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 30 | 50 | $16,250 | $3,777 | 23.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 12 | 12 | $7,296 | $1,627 | 22.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 16 | 17 | $3,740 | $763.03 | 20.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 37 | 113 | $28,476 | $6,607 | 23.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 19 | 46 | $16,376 | $3,826 | 23.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 32 | 54 | $8,856 | $1,843 | 20.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 12 | 12 | $6,480 | $1,543 | 23.8% |
About Dr. Rom Leidner, MD
Dr. Rom Leidner, MD is a Hematology & Oncology healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801908702.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rom Leidner, MD has received a total of $79,796 in payments from pharmaceutical and medical device companies, with $4,586 received in 2024. These payments were reported across 118 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($40,983).
As a Medicare-enrolled provider, Leidner has provided services to 338 Medicare beneficiaries, totaling 853 services with total Medicare billing of $76,874. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Medical Oncology
- Location Portland, OR
- Active Since 08/31/2006
- Last Updated 03/19/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1801908702
Products in Payments
- LIBTAYO (Drug) $14,287
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $12,566
- KEYTRUDA (Biological) $10,721
- NO PRODUCT DISCUSSED (Drug) $6,893
- LIBTAYO (Biological) $1,101
- OPDIVO (Biological) $392.87
- NA (Device) $171.90
- Lenvima (Drug) $124.38
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Portland
Brian Druker, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Dr. Jay Andersen, M.d, M.D
Hematology & Oncology — Payments: $480,702
Hematology & Oncology $480,702
Rachel Sanborn, Md, MD
Hematology & Oncology — Payments: $322,427
Hematology & Oncology $322,427
Richard Maziarz, Md, MD
Hematology & Oncology — Payments: $246,109
Hematology & Oncology $246,109
Tibor Kovacsovics, Md, MD
Hematology & Oncology — Payments: $245,023
Hematology & Oncology $245,023
John Godwin, Md, MD
Hematology & Oncology — Payments: $96,623
Hematology & Oncology $96,623